stockrow
Saturday 7 November 2026
Export OKUR’s income statement to Excel — free account
OnKure Therapeutics, Inc.
OKUR Healthcare Biotechnology
- EPS
- +67.2%
- Free cash flow
- +22.1%
Quarter to September 2026, against a year earlier
2.79
0.26
+10.28%
Follow OKUR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
18.84 | 26.75 | 13.78 | 10.28 |
+8 more quarters Free account |
Net Debt/EBITDA |
8.54 | 10.56 | 12.46 | 4.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.67 | 0.85 | 0.85 | |
Capex/Depreciation |
(0.14) | (0.02) | (0.02) | (0.04) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.26) | (0.21) | (0.95) | (0.85) | |
Cash per Share |
3.27 | 3.54 | 14.05 | 4.37 | |
Shareholders Equity per Share |
3.16 | 3.45 | 13.48 | 4.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.16 | 3.45 | 13.48 | 4.16 | |
Free Cash Flow |
(13.11) | (10.36) | (12.94) | (11.52) | |
Working Capital |
156.80 | 171.03 | 183.15 | 54.92 | |
Capital Expenditures |
(0.03) | 0.00 | 0.00 | (0.01) | |
Net Current Asset Value |
156.25 | 170.43 | 183.14 | 54.91 | |
| Other line items | |||||
Quick Ratio |
18.58 | 26.55 | 13.41 | 9.97 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.26) | (0.21) | (0.95) | (0.85) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.80 | 2.19 | 6.68 | 2.20 | |
Average Assets |
119.96 | 132.71 | 149.29 | 88.51 | |
Average Common Equity |
112.08 | 125.14 | 137.50 | 80.01 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026